Bibliographic Info
GuidelineWHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
Status
Updated
Recommended in favor
Conditional
Certainty of evidence
Very low
Longer regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB): Ethionamide or prothionamide may be included in the treatment of MDR/RR-TB patients on longer regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used, or if better options to compose a regimen are not possible